NCT06438523

Brief Summary

Clinical and radiographic assessment of A-prf,A-prf combined with nanochitosan compared to chitosan for symptomatic irreversible pulpits in lower permanent first molar

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 2, 2023

Completed
9 months until next milestone

First Submitted

Initial submission to the registry

May 15, 2024

Completed
19 days until next milestone

First Posted

Study publicly available on registry

June 3, 2024

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 2, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

September 2, 2025

Completed
Last Updated

June 3, 2024

Status Verified

May 1, 2024

Enrollment Period

1.7 years

First QC Date

May 15, 2024

Last Update Submit

May 30, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • pain assessment

    Pain assessment using numerical rate scale

    6,12,24,72hours and 7 days postoperative

Secondary Outcomes (1)

  • Clinical and radiographic success

    1,3,6,9and 12 months

Study Arms (3)

Advanced Platelet rich fibrin,A-prf,A-PRF scaffold

EXPERIMENTAL

A-PRF will be prepared according to Choukroun's technique by drawing whole blood from the median cubital vein into a 10 ml plain plastic test tubes (non-citrated) without the addition of an anticoagulant reagent . To prevent the blood from coagulating, it will be centrifuged immediately using a table top centrifuge at 1500 rpm for 14 minute.

Procedure: PULPOTOMY OF MATURE PERMENANT TEETH

A-prf mixed with nano chitosan

EXPERIMENTAL

A-PRF will be prepared according to Choukroun's technique by drawing whole blood from the median cubital vein into a 10 ml plain plastic test tubes (non-citrated) without the addition of an anticoagulant reagent . To prevent the blood from coagulating, it will be centrifuged immediately using a table top centrifuge at 1500 rpm for 14 minute then mixed with nanochitosan

Procedure: PULPOTOMY OF MATURE PERMENANT TEETH

chitosan

EXPERIMENTAL

he access cavity will be prepared up to the level of pulp chamber floor using sterile round diamond bur size 1 in high-speed hand piece with coolant.Once the pulp has been reached, a sharp sterile excavator should be used to remove the pulp tissue to the level of the radicular/root canal orifices then chitosan will be applied

Procedure: PULPOTOMY OF MATURE PERMENANT TEETH

Interventions

Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp

A-prf mixed with nano chitosanAdvanced Platelet rich fibrin,A-prf,A-PRF scaffoldchitosan

Eligibility Criteria

Age15 Years - 30 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Patients suffering from Symptomatic irreversible pulpitis in mature mandibular molars only will be involved.
  • Patients of either gender aged from 15-30.
  • Tooth should give positive response to cold test.
  • Haemostasias should be achieved after total pulpotomy.
  • The tooth is restorable and free from advanced periodontal disease, cracks and splits.
  • Patients should be free from any systemic disease that may affect normal healing and predictable outcome.
  • Patients who will agree to the consent and will commit to follow-up period.
  • Patients with mature root.
  • Patients with no internal or external resorption and no periapical lesions.
  • Soft tissues around the tooth are normal with no swelling or sinus tract.

You may not qualify if:

  • Patients with immature roots.
  • Haemostasias after 10 minutes can not be controlled after total pulpotomy
  • Patients with any systemic disease that may affect normal healing.
  • Patients with periapical lesions or infections.
  • Pregnant females.
  • Patients who could/would not participate in a 6 months follow-up.
  • Patients with fistula or swelling
  • Patients with necrotic pulp.
  • Patients with old age.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Future university

Cairo, Fifth Settlement, 11813, Egypt

RECRUITING

Study Officials

  • wael H Kamel, Prof.

    Future University in Egypt

    STUDY DIRECTOR
  • Hani s sadek, Prof.

    Future University in Egypt

    PRINCIPAL INVESTIGATOR

Central Study Contacts

mai S abdelwahed, Bachelor

CONTACT

Hala s abdelwahed, student

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Intervention: Intervention 1 : Vital pulp therapy using A-PRF as capping material. Intervention 2 : Vital pulp therapy using A-PRF mixed with Nano-Chitosan as capping material. Control/Comparator: Vital pulp therapy using Chitosan as capping material.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Researcher

Study Record Dates

First Submitted

May 15, 2024

First Posted

June 3, 2024

Study Start

September 2, 2023

Primary Completion

May 2, 2025

Study Completion

September 2, 2025

Last Updated

June 3, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share

Locations